Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$266.04M+590.57%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Nikhil Lalwani
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 970
- Beta
- 0.45
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 2.59
Financials
Revenue
$266.04M+590.6%Net Income
$24.71M+878.3%EBITDA
$60.37M+335.4%Free Cash Flow
$67.99MEPS (diluted)
$1.05+377.3%Shares Outstanding (diluted)
21.91M+88.5%Operating Expenses
$106.41MCash & Debt
$375.87MReturn of Capital
$813.0KRevenue by Segment (annual)
$883.37MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $883.37M | $78.34M | $3.50 |
| 2024 | $614.38M | $-18.52M | $-1.04 |
| 2023 | $486.82M | $18.78M | $0.95 |
| 2022 | $316.38M | $-47.90M | $-3.05 |
| 2021 | $216.14M | $-42.60M | $-3.40 |
| 2020 | $208.47M | $-22.55M | $-1.88 |
| 2019 | $206.55M | $6.09M | $0.51 |
| 2018 | $201.58M | $15.49M | $1.33 |
| 2017 | $176.84M | $-1.08M | $-0.09 |
| 2016 | $128.62M | $3.93M | $0.34 |
| 2015 | $76.32M | $15.38M | $1.34 |
| 2014 | $55.97M | $28.75M | $2.61 |
| 2013 | $30.08M | $301.0K | $-0.92 |
| 2012 | $2.30M | $-27.72M | $-7.64 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $5.74
- Implied price
- $132.02
- Return from $72.18
- 12.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $65.64 — -9.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 17 | 20 | 23 | 26 | 29 |
|---|---|---|---|---|---|
| -2.0% | -3.6% | -0.4% | 2.4% | 4.9% | 7.2% |
| 3.0% | 1.3% | 4.6% | 7.6% | 10.3% | 12.7% |
| 8.0% | 6.2% | 9.7% | 12.8% | 15.6% | 18.2% |
| 13.0% | 11.1% | 14.8% | 18.1% | 21.0% | 23.7% |
| 18.0% | 16.1% | 19.9% | 23.3% | 26.3% | 29.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (9)
- Newsglobenewswire.com·6d ago·Neutral
ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting Data from Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial will be presented in a late-breaking oral presentation during Uveitis Subspecialty Day 2026
View source ↗ - Newszacks.com·7d ago·Neutral
Implied Volatility Surging for ANI Pharmaceuticals Stock Options Investors need to pay close attention to ANIP stock based on the movements in the options market lately.
View source ↗ - Newsseekingalpha.com·11d ago·Neutral
ANI Pharmaceuticals: Cortrophin's Q4 Test, With Generics Funding The Build ANI Pharmaceuticals is rated Buy, with a fair value of $104, offering 38% upside from current levels. Generics generate strong EBITDA and cash, funding rare-disease expansion; rare disease is expected to comprise nearly 60% of 2026 revenue. Cortrophin guidance was lowered by ~$30M, but H2 expectations remain intact, with Q4 growth hinging on gout salesforce productivity.
View source ↗ - Newsglobenewswire.com·13d ago·Negative
…he FDA Approval of Everolimus Tablets for Oral Suspension PRINCETON, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), for Everolimus Tablets for Oral Suspension 2mg, 3mg and 5mg. ANI's Everolimus Tablets for Oral Suspension are the generic version of the reference listed drug (RLD) Afinitor Disperz®…
View source ↗ - Newsseekingalpha.com·21d ago·Positive
ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·33d ago·Positive
ANI Pharmaceuticals to Present at September Investor Conferences PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company's executive leadership team, will participate in fireside chats at the following upcoming investor conferences:
View source ↗ - Newszacks.com·52d ago·Negative
ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth Cortrophin guidance cuts put more pressure on ANI Pharmaceuticals' second-half execution as the drug must deliver a sharper growth ramp.
View source ↗ - Newszacks.com·52d ago·Positive
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk? ANI Pharmaceuticals' low valuation and strong 2026 growth outlook face a key test as Cortrophin execution risk rises.
View source ↗ - Newszacks.com·56d ago·Neutral
ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut ANI Pharmaceuticals tops Q2 earnings and sales estimates, but shares fall as the company cuts its 2026 Cortrophin Gel revenue outlook.
View source ↗
Earnings
Fri, Nov 6(in 4 weeks)
Consensus estimate $2.17 per share
Typical surprise +17.2% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 7$2.21 vs $2.04beat
- Fri, May 8$2.05 vs $1.28beat
- Fri, Feb 27$2.33 vs $1.99beat
- Fri, Nov 7$2.04 vs $1.74beat
- Fri, Aug 8$1.80 vs $1.38beat
- Fri, May 9$1.70 vs $1.37beat
Estimates and results for ANIP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ANIP officers and directors.
- Bought
- —
- Sold
- $12.6m
0 trades
40 trades
- Carey Stephen P.sold
- Lalwani Nikhilsold
- Cook Meredithsold
- Thoma Jeannesold
- Carey Stephen P.sold
- Lalwani Nikhilsold
- Cook Meredithsold
- Gutwerg Orisold
60 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ANIP.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.